Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $25.00 at BTIG Research

Posted by Brian Himes on Jul 30th, 2026

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) had its price target hoisted by investment analysts at BTIG Research from $24.00 to $25.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price objective suggests a potential upside of 10.82% from the stock’s previous close.

Several other research firms have also issued reports on ADPT. JPMorgan Chase & Co. dropped their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. Morgan Stanley upped their price objective on Adaptive Biotechnologies from $18.00 to $20.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. Guggenheim reissued a “buy” rating on shares of Adaptive Biotechnologies in a report on Thursday. Finally, TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, July 15th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Adaptive Biotechnologies has a consensus rating of “Moderate Buy” and a consensus target price of $21.33.

View Our Latest Report on ADPT

Adaptive Biotechnologies Trading Up 0.2%

Shares of ADPT stock opened at $22.56 on Thursday. Adaptive Biotechnologies has a 1 year low of $9.96 and a 1 year high of $23.15. The firm’s fifty day moving average price is $19.05 and its two-hundred day moving average price is $16.56. The firm has a market capitalization of $3.61 billion, a P/E ratio of -68.36 and a beta of 2.07.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. The firm had revenue of $70.87 million for the quarter, compared to analysts’ expectations of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The company’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.20) EPS. As a group, equities research analysts forecast that Adaptive Biotechnologies will post -0.47 EPS for the current fiscal year.

Insider Activity

In other Adaptive Biotechnologies news, insider Susan Bobulsky sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $19.00, for a total value of $95,000.00. Following the sale, the insider owned 411,775 shares in the company, valued at $7,823,725. This represents a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harlan S. Robins sold 492,400 shares of the company’s stock in a transaction that occurred on Tuesday, July 21st. The shares were sold at an average price of $21.89, for a total value of $10,778,636.00. Following the completion of the sale, the insider owned 812,058 shares in the company, valued at $17,775,949.62. This represents a 37.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,305,787 shares of company stock valued at $27,828,563. Company insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ADPT. California State Teachers Retirement System lifted its holdings in Adaptive Biotechnologies by 1.0% during the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock valued at $1,145,000 after purchasing an additional 933 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Adaptive Biotechnologies by 6.8% in the first quarter. PNC Financial Services Group Inc. now owns 14,737 shares of the company’s stock valued at $205,000 after purchasing an additional 941 shares during the last quarter. Captrust Financial Advisors raised its position in shares of Adaptive Biotechnologies by 7.6% in the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock valued at $184,000 after purchasing an additional 1,119 shares during the period. Assetmark Inc. raised its position in shares of Adaptive Biotechnologies by 46.4% in the first quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock valued at $61,000 after purchasing an additional 1,401 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Adaptive Biotechnologies by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company’s stock worth $120,000 after buying an additional 1,532 shares during the last quarter. 99.17% of the stock is owned by institutional investors and hedge funds.

Adaptive Biotechnologies News Summary

Here are the key news stories impacting Adaptive Biotechnologies this week:

Positive Sentiment: Adaptive reported a second-quarter loss of approximately $0.10 per share, better than the $0.13 loss analysts expected and an improvement from a $0.17 loss in the year-ago period. Adaptive Biotechnologies Reports Q2 Loss, Beats Revenue Estimates
Positive Sentiment: Revenue reached $71.55 million, surpassing the $65.44 million consensus estimate and increasing 21.5% year over year. The revenue beat supports investor confidence in demand for the company’s immune-sequencing and diagnostic offerings. Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
Positive Sentiment: The earnings call and follow-up coverage are giving investors additional detail on quarterly operating metrics and management’s outlook, with the headline results reinforcing expectations for continued growth and improving losses. Adaptive Biotechnologies Q2 2026 Earnings Call Transcript
Neutral Sentiment: Analyst sentiment remains broadly favorable, with five Buy ratings, one Hold and one Sell, producing a “Moderate Buy” consensus. However, the average price target of $20.83 is below the current share price, limiting near-term upside implied by published targets.
Negative Sentiment: Insider Harlan Robins sold 492,400 shares worth about $10.8 million, reducing his holdings by 37.75%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary bearish signal but may still weigh on sentiment. Adaptive Biotechnologies Insider Sale

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.